Apellis Pharmaceuticals, Inc. (APLS) Stock Price, Financials & Summary

Price chart

Apr 16Apr 21Apr 24Apr 29May 4May 7May 12May 15

Key dataMay 15, 2026

Open$41.05

From 52W high−0.22%

Volume28.64M

Market cap$5.25B

P/E (TTM)38.7x

P/S (TTM)4.8x

Div yield—

Key dataMay 15, 2026

Open

$41.05

From 52W high

−0.22%

Volume

28.64M

Market cap

$5.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.0x

P/E (TTM)

38.7x

RSI (14)

84.5

MomentumView details →

1D Return

+0.00%

YTD Return

+63.34%

SummaryUpdated Mar 1, 2026

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company founded in 2009 and based in Waltham, Massachusetts. The company went public in November 2017 and focuses on developing and commercializing therapeutic compounds that target the complement system, a critical component of the body's immune defense mechanism. Apellis has successfully transitioned from a development-stage company to a commercial enterprise with two approved products generating significant revenue, while maintaining a robust pipeline of complement-based therapies for various autoimmune and inflammatory diseases.

Ask drillr about Apellis Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

38.7x

EV/EBITDA

30.0x

EV/Sales

4.8x

P/S (TTM)

4.8x

P/B (TTM)

12.7x

ProfitabilityView details →

Gross Margin

90.12%

Net Margin

12.06%

EBITDA Margin

16.03%

ROE (TTM)

32.12%

ROA (TTM)

12.31%

Asset Turnover

1.02x

GrowthView details →

Revenue YoY

+42.46%

EPS YoY

+159.22%

FCF YoY

+549.16%

Revenue CAGR 3Y

+136.98%

EPS CAGR 3Y

+111.25%

EBITDA YoY

+200.61%

MomentumView details →

1D Return

+0.00%

YTD Return

+63.34%

1Y Return

+135.13%

RSI (14)

84.5

vs 50D SMA

+23.59%

vs 200D SMA

+57.34%

Capital & dividendView details →

Debt/Equity

1.15x

Current Ratio

3.63x

Quick Ratio

3.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.15

EPS Surprise

139.47%

Beats (12Q)

7/12

Next Q EPS Est

—

Avg Surprise (4Q)

62.06%

Rev Surprise

27.47%

Financials snapshotView financials →

Revenue (TTM)

1.11B

Net Income (TTM)

133.27M

Op. CF (TTM)

37.77M

Latest newsMore news →

Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.86d ago

Similar companies

博拓生物688767.SH Abbisko Cayman Limited02256.HK Erasca, Inc.ERAS CK Life Sciences Int'l., (Holdings) Inc.00775.HK Dianthus Therapeutics, Inc.DNTH PTC Therapeutics, Inc.PTCT Find similar companies →

Latest newsMore news →

The U.S. Court of Appeals for the First Circuit affirmed the dismissal of a putative securities class action against Apellis Pharmaceuticals and its CEO, holding that the company's statements about clinical trial results were not actionable half-truths.18d ago Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.86d ago